The enhanced allocation will be directed toward expanding healthcare infrastructure, increasing patient capacity, and widening acces
Landmark procedure restores 32-year-old CKD patient’s health, highlighting how public insurance is widening access to advanced renal care
There are limited treatment options available for patients living with non-diabetic CKD, and the unmet need is high for new treatments to delay kidney disease progression and reduce cardiovascular risk
Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients
Primary membranous nephropathy is a chronic autoimmune disease that attacks the kidneys’ filtering units
NGD Infection Prevention was formed to scale the delivery of sequence-based transmission detection
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
Deceased donor kidney transplants are time-critical, and it is uncommon to attempt them robotically
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
Revenues up 13.1% year-over-year; Continued momentum driven by organic growth, strategic partnerships, and acquisitions
Subscribe To Our Newsletter & Stay Updated
